📊 ICCC Key Takeaways
Is Immucell Corp. /DE/ (ICCC) a Good Investment?
ImmuCell demonstrates exceptional financial health with 45% gross margins, 19% operating margins, and strong free cash flow conversion (32.8% FCF margin), supported by conservative leverage (0.30x D/E) and fortress-like liquidity (4.82x current ratio). However, modest revenue growth of 4.3% YoY and low capital returns (6.7% ROE, 4.4% ROA) limit upside potential, suggesting a stable, profitable business lacking significant growth momentum.
ImmuCell’s fundamentals are improving: positive operating income and free cash flow with a solid 41% gross margin and strong liquidity indicate a healthier core business despite a small GAAP loss. Moderate leverage and adequate interest coverage provide runway for scaling; sustaining revenue growth and operating leverage should tip results to consistent profitability.
Why Buy Immucell Corp. /DE/ Stock? ICCC Key Strengths
- Exceptional profitability margins (45% gross, 19% operating, 18.7% net) indicating pricing power and operational efficiency
- Outstanding balance sheet with 4.82x current ratio and 0.30x debt-to-equity providing substantial financial flexibility
- Strong free cash flow generation ($3.4M FCF, 32.8% FCF margin) with minimal capital intensity ($177.2K CapEx)
- Strong liquidity (4.26x current, 1.93x quick)
- Positive free cash flow (4.4% margin) and operating income
- Healthy gross margin (41.4%) with moderate leverage (0.34x D/E)
ICCC Stock Risks: Immucell Corp. /DE/ Investment Risks
- Anemic revenue growth of 4.3% YoY is concerning for a diagnostic/biotech company needing scale
- Low return on equity (6.7%) and return on assets (4.4%) suggest inefficient capital deployment or underutilization of asset base
- Small absolute revenue base ($10.4M) limits ability to fund R&D, market expansion, or acquisitions necessary for competitive positioning
- Net losses persist (net margin -3.8%) hurting ROE/ROA
- Modest revenue growth (+4.3% YoY) may limit scale benefits
- Interest coverage only 3.8x; margins sensitive to cost/volume
Key Metrics to Watch
- Revenue growth acceleration and year-over-year trends in top-line
- Free cash flow sustainability and capital allocation decisions
- Return on equity and asset efficiency improvements
- Operating margin and sustained FCF generation
- Revenue growth pace and gross margin stability
Immucell Corp. /DE/ (ICCC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 32.8% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 4.82x current ratio provides a solid financial cushion.
ICCC Profit Margin, ROE & Profitability Analysis
ICCC vs Healthcare Sector: How Immucell Corp. /DE/ Compares
How Immucell Corp. /DE/ compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immucell Corp. /DE/ Stock Overvalued? ICCC Valuation Analysis 2026
Based on fundamental analysis, Immucell Corp. /DE/ has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immucell Corp. /DE/ Balance Sheet: ICCC Debt, Cash & Liquidity
ICCC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Immucell Corp. /DE/'s revenue has grown significantly by 49% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.26 indicates the company is currently unprofitable.
ICCC Revenue Growth, EPS Growth & YoY Performance
ICCC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.1M | $1.4M | $0.16 |
| Q3 2025 | $5.5M | -$139.7K | $-0.02 |
| Q3 2023 | $4.8M | -$655.1K | $-0.08 |
| Q3 2022 | $4.8M | $147.8K | $-0.02 |
| Q2 2018 | $1.7M | -$218.4K | $-0.05 |
| Q1 2018 | $2.9M | -$168.1K | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Immucell Corp. /DE/ Dividends, Buybacks & Capital Allocation
ICCC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immucell Corp. /DE/ (CIK: 0000811641)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ICCC
What is the AI rating for ICCC?
Immucell Corp. /DE/ (ICCC) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 73% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ICCC's key strengths?
Claude: Exceptional profitability margins (45% gross, 19% operating, 18.7% net) indicating pricing power and operational efficiency. Outstanding balance sheet with 4.82x current ratio and 0.30x debt-to-equity providing substantial financial flexibility. ChatGPT: Strong liquidity (4.26x current, 1.93x quick). Positive free cash flow (4.4% margin) and operating income.
What are the risks of investing in ICCC?
Claude: Anemic revenue growth of 4.3% YoY is concerning for a diagnostic/biotech company needing scale. Low return on equity (6.7%) and return on assets (4.4%) suggest inefficient capital deployment or underutilization of asset base. ChatGPT: Net losses persist (net margin -3.8%) hurting ROE/ROA. Modest revenue growth (+4.3% YoY) may limit scale benefits.
What is ICCC's revenue and growth?
Immucell Corp. /DE/ reported revenue of $10.4M.
Does ICCC pay dividends?
Immucell Corp. /DE/ does not currently pay dividends.
Where can I find ICCC SEC filings?
Official SEC filings for Immucell Corp. /DE/ (CIK: 0000811641) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ICCC's EPS?
Immucell Corp. /DE/ has a diluted EPS of $0.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ICCC a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Immucell Corp. /DE/ has a BUY rating with 73% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ICCC stock overvalued or undervalued?
Valuation metrics for ICCC: ROE of 6.7% (sector avg: 15%), net margin of 18.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ICCC stock in 2026?
Our dual AI analysis gives Immucell Corp. /DE/ a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ICCC's free cash flow?
Immucell Corp. /DE/'s operating cash flow is $3.6M, with capital expenditures of $177.2K. FCF margin is 32.8%.
How does ICCC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 18.7% (avg: 12%), ROE 6.7% (avg: 15%), current ratio 4.82 (avg: 2).